An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study
Authors
Keywords
-
Journal
Expert Review of Pharmacoeconomics & Outcomes Research
Volume 18, Issue 4, Pages 435-446
Publisher
Informa UK Limited
Online
2018-04-20
DOI
10.1080/14737167.2018.1464394
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review
- (2016) Mahdi Gharaibeh et al. PHARMACOECONOMICS
- Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer
- (2016) Mahdi Gharaibeh et al. JOURNAL OF MEDICAL ECONOMICS
- Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer
- (2015) M Gharaibeh et al. BRITISH JOURNAL OF CANCER
- Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer
- (2015) K. Lien et al. Current Oncology
- Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study
- (2015) Alfredo Carrato et al. Expert Review of Pharmacoeconomics & Outcomes Research
- SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients
- (2014) Neil Desai et al. Translational Oncology
- Cost-effectiveness of systemic therapies for metastatic pancreatic cancer
- (2013) V.C. Tam et al. Current Oncology
- nab-Paclitaxel mechanisms of action and delivery
- (2013) Denise A. Yardley JOURNAL OF CONTROLLED RELEASE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Conceptualizing a Model
- (2012) Mark Roberts et al. MEDICAL DECISION MAKING
- nab -Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
- (2012) Kristopher K. Frese et al. Cancer Discovery
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2011) Dorothy Romanus et al. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
- Catalogue of EQ-5D Scores for the United Kingdom
- (2011) Patrick W. Sullivan et al. MEDICAL DECISION MAKING
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elicitation of health state utilities in metastatic renal cell carcinoma
- (2010) Paul Swinburn et al. CURRENT MEDICAL RESEARCH AND OPINION
- Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status
- (2008) Neil P. Desai et al. ANTI-CANCER DRUGS
- Health state utilities for non small cell lung cancer
- (2008) Beenish Nafees et al. Health and Quality of Life Outcomes
- Health state utility scores in advanced non-small cell lung cancer
- (2008) Scott Doyle et al. LUNG CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started